You may recall in a previous article I discussed the implications of Nanobots (nanotechnology robots) and how I expected it to be replacing much of the current medical technology as early as the 2020’s.
In that article I explained that nanotechnology was already able to mimic a dog’s olfactory system so well that it could detect explosives and other substances with the aim of making portable, accurate explosive sniffing devices. This technology was made possible in 2012 from the merging of mechanical engineering and chemistry.
Of course, bioengineering itself in Pharma is by no means new as it has been used for pacemakers and deep brain stimulation implantable pulse generators for Parkinson’s for many years. However, what makes this new and exciting is that they are taking it to a new level so that the implantable generators become part of the patient’s circuitry to either regulate drugs or, in fact, eliminate the need for them entirely. GSK are aiming to have this achieved in the next decade.
Conclusion
I applaud GSK’s efforts in this and believe that this is what real innovation in Pharma is all about. We need to start thinking seriously beyond the pill and real patient centricity. They are focusing on what the ideal world is for the patient and working towards achieving that – with or without pills.
Found this article interesting?
To learn more about how Eularis can help you find the best solutions to the challenges faced by healthcare teams, please drop us a note or email the author at abates@eularis.com.